Know Cancer

forgot password

Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy

Phase 2
18 Years
Open (Enrolling)
Multiple Myeloma, Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma

Thank you

Trial Information

Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy

Primary Objective: I. To determine the proportion of patients reaching a stem cell yield of
3 million CD34 cells/kg by second day of apheresis with intravenously administered AMD3100
among patients receiving primary therapy for myeloma with lenalidomide. Secondary
Objectives: I. Safety and tolerability of intravenously administered AMD3100. II. Rate of
failure to mobilize. Outline: Patients receive plerixafor IV on days 5-8 and filgrastim
subcutaneously on days 1-8 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at 30 days.

Inclusion Criteria

Inclusion - Absolute neutrophil count >= 1000/uL - Platelet >= 75000/uL -
Hemoglobin >= 8.0 g/dL - Serum aspartate aminotransferase (AST)/serum glutamic
oxaloacetic transaminase (SGOT), serum alanine aminotransferase (ALT)/serum glutamic
pyruvic transaminase (SGPT) and total bilirubin < 2 x upper limit of normal (ULN) -
Confirmed diagnosis of multiple myeloma, requiring therapy - Initial treatment for
symptomatic myeloma using a lenalidomide based treatment regimen, started =< 12 months
prior to registration - Received at least 2 cycles of treatment with the lenalidomide
regimen - Last dose of lenalidomide > 2 weeks prior to registration - Eligible
to undergo autologous transplantation - ECOG performance status (PS) 0 or 1 -
Willingness to return for follow-up - Provide informed written consent -
Adequate cardiopulmonary function: ejection fraction >= 45%, corrected pulmonary diffusion
capacity of >= 50%, FEV1 >= 50%, FVC >= 50% - Negative serum or urine pregnancy test
done =< 7 days prior to registration, for women of childbearing potential only Exclusion
- A co-morbid condition which, in the view of the Investigators, renders the patient
at high risk from treatment complications - Active malignancy with the exception of
non melanoma skin cancer or in situ cervical or breast cancer - Other co-morbidity
which would interfere with patient's ability to participate in the trial, e.g.
uncontrolled infection, uncompensated heart or lung disease - Other concurrent
chemotherapy, radiotherapy, or any ancillary therapy considered investigational - Use
of cyclophosphamide as part of stem cell mobilization - Use of more than one regimen
for treatment of symptomatic myeloma - Dialysis dependent renal failure -
Pregnant women or women of reproductive ability who are unwilling to use effective
contraception - Nursing women - Men who are unwilling to use a condom (even if
they have undergone a prior vasectomy) while having intercourse with any woman, while
taking the drug and for 4 weeks after stopping treatment - Acute infection, active
HIV infection

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Patients Achieving 3 Million CD34 Cells/kg After 2 Days of Apheresis

Outcome Description:

Number of CD34 cells/kg collected on days 1-2. Apheresis is the process when blood is taken out through a catheter in a vein in one arm, blood is sent through a machine that takes out the stem cells and the rest of the blood is then returned through a vein in your other arm.

Outcome Time Frame:

After 2 days of apheresis

Safety Issue:


Principal Investigator

Shaji Kumar, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Mayo Clinic


United States: Food and Drug Administration

Study ID:




Start Date:

December 2009

Completion Date:

December 2012

Related Keywords:

  • Multiple Myeloma
  • Refractory Multiple Myeloma
  • Stage I Multiple Myeloma
  • Stage II Multiple Myeloma
  • Stage III Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Mayo ClinicRochester, Minnesota  55905
Mayo Clinic in ArizonaScottsdale, Arizona  85259-5404